Why GLP-1 Meds May Not Be Working Yet
Not seeing results on GLP-1 meds like semaglutide? Learn why that might be, and how lifestyle changes and medical support could help you stay on track.
- Weight-related outcomes may take time and are influenced by multiple factors, including adherence and lifestyle.
- Plateaus are common and may signal the need for reassessment, not treatment failure.
- Individual response can vary based on metabolic health, stress, sleep, and more.
- Consistent medication use and supportive lifestyle strategies can help optimize results.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic®, Rybelsus®) and chronic weight management (Wegovy®). It has been shown to help support appetite regulation and improve markers of metabolic health in eligible individuals. However, not everyone experiences immediate or consistent results. If you’re wondering why semaglutide is not working, there are several reasons this may be happening, and actionable steps to help get back on track.
Note: Eden partners with licensed healthcare providers who evaluate patients individually. GLP-1 medications may be prescribed based on medical judgment and are not dispensed directly by Eden.
What Is Semaglutide?
Semaglutide mimics the GLP-1 hormone, which plays a role in glucose regulation and appetite signaling. FDA-approved versions include:
- Wegovy® – Approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.
- Ozempic® – Approved for adults with type 2 diabetes to improve glycemic control.
- Rybelsus® – An oral GLP-1 approved for type 2 diabetes.
Licensed healthcare providers, at their discretion, may determine that semaglutide is appropriate for uses beyond its FDA-approved indications. Any such decision requires a personalized discussion between the patient and provider about potential risks, benefits, and alternatives. Eden connects patients with independent, licensed medical professionals who assess eligibility for treatment options.
How Semaglutide May Support Metabolic Health
While semaglutide is approved for specific medical uses, many patients report that, when combined with diet and physical activity, it may:
- Help reduce hunger and increase feelings of fullness
- Support more consistent eating habits
- Encourage reduced intake of energy-dense foods
- Promote improved insulin sensitivity
Disclaimer: Any descriptions of potential benefits are for informational purposes only and are not intended to suggest FDA approval. These statements have not been evaluated by the FDA, and individual results will vary based on health status and provider guidance.
{{primary-cta}}
10 Reasons Semaglutide May Not Be Working
- Too Early to See Results
Weight-related changes may take several weeks. Full benefits often appear after 12–20 weeks of consistent use.
Supporting Study: Once-Weekly Semaglutide in Adults with Overweight or Obesity - Subtherapeutic or Initial Dosing
Lower starting doses may not result in significant changes. Semaglutide is typically titrated gradually to minimize side effects. - Inconsistent Use
GLP-1 levels rely on regular administration. Missing doses or inconsistent use may reduce effectiveness. - Nutrition Not Aligned
Medications work best alongside a nutrient-dense, calorie-aware eating plan. Overeating or poor food quality can blunt progress. - Limited Physical Activity
Physical activity helps maintain lean muscle and supports healthy metabolism. Without movement, weight-related benefits may slow. - Underlying Conditions
Conditions such as PCOS, hypothyroidism, or insulin resistance can influence how the body responds. Medical evaluation is essential. - Elevated Stress
Chronic stress may interfere with appetite and metabolism. Managing stress levels is key to overall health. - Poor Sleep
Sleep deprivation impacts hormones tied to hunger and cravings. Aim for consistent, restorative sleep. - Lack of Tracking
Monitoring food intake, weight changes, and other metrics helps identify what’s working and where to adjust. - Unrealistic Timelines
Weight reduction is gradual. Expecting rapid results can lead to frustration. Sustainable progress takes time.
What to Do if Semaglutide Seems to Stop Working
Even when used correctly, it’s common to experience plateaus. This doesn’t mean semaglutide isn’t working, it may just be time to make adjustments.
Why Plateaus May Happen
- Natural metabolic adaptation
- Decrease in resting energy expenditure
- Shifts in hunger and satiety hormones
What May Help:
- Reassess your dose (under medical supervision)
- Incorporate resistance training, which may preserve muscle
- Adjust nutrition, under licensed medical supervision - consider macronutrient balance
- Discuss alternatives with your licensed healthcare provider (e.g., tirzepatide or adjunct therapies)
How to Optimize Your Response
- Stay Consistent with Medication
Take semaglutide at the same time each week, as prescribed. - Emphasize Nutrition
- Prioritize protein and fiber
- Choose whole, unprocessed foods
- Stay hydrated and mindful of portion sizes
- Prioritize protein and fiber
- Move Your Body (If Deemed Medically Appropriate)
- Aim for 150+ minutes of moderate-intensity exercise per week
- Add strength training twice weekly
- Include daily movement (walks, stretching)
- Aim for 150+ minutes of moderate-intensity exercise per week
- Prioritize Sleep and Recovery
- Sleep 7–9 hours nightly
- Limit screen time before bed
- Incorporate stress-reduction routines (e.g., journaling, meditation)
- Sleep 7–9 hours nightly
- Track and Reflect
Use a food log, scale, or photos to monitor progress. Talk to your licensed healthcare provider if results slow or side effects arise.
{{primary-cta}}
Final Thoughts
If you’re concerned that semaglutide is not working, you’re not alone. Many individuals experience slow starts, temporary stalls, or fluctuating progress. The key is to stay consistent, communicate with your licensed medical care team, and make small changes that align with your health goals.
Eden helps connect individuals with licensed healthcare providers who can assess your needs and determine whether GLP-1 therapy is appropriate. If you're already prescribed semaglutide and have hit a plateau, a few strategic tweaks could make all the difference.
Disclaimer:
This blog is for informational purposes only and does not constitute medical advice. Semaglutide and other GLP-1 medications must be prescribed by a licensed medical provider following a medical evaluation. Eden does not dispense medications but facilitates care with third-party providers and pharmacies. Use of semaglutide for purposes beyond its FDA-approved indications should only occur under the guidance of a licensed healthcare provider, with appropriate clinical oversight and informed consent.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by state-licensed pharmacies. Please consult a licensed healthcare provider before making any medical decisions.
Frequently asked questions
Blog Components

References
Chang, R. S., Hu, J., & Yeh, H. (2022). Once-Weekly Semaglutide with Lifestyle Intervention Results in Clinically Significant Weight Loss. Journal of General Internal Medicine, 37(7), 1824–1826. https://doi.org/10.1007/s11606-021-07215-4
Hall, K. D. (2024). Physiology of the weight‐loss plateau in response to diet restriction, GLP‐1 receptor agonism, and bariatric surgery. Obesity, 32(6), 1163–1168. https://doi.org/10.1002/oby.24027
Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024a). Real-World Use of Semaglutide for weight management: Patient Characteristics and Dose Titration—A Danish Cohort study. Diabetes Care, 47(10), 1834–1837. https://doi.org/10.2337/dc24-1082
Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024b). Real-World Use of Semaglutide for weight management: Patient Characteristics and Dose Titration—A Danish Cohort study. Diabetes Care, 47(10), 1834–1837. https://doi.org/10.2337/dc24-1082
Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024c). Real-World Use of Semaglutide for weight management: Patient Characteristics and Dose Titration—A Danish Cohort study. Diabetes Care, 47(10), 1834–1837. https://doi.org/10.2337/dc24-1082
Pa-C, C. F. (2025, April 7). How semaglutide affects sleep: Exploring its role in sleep Disorder management. Bmi Doctors. https://bmidoctors.com/how-semaglutide-affects-sleep-exploring-its-role-in-sleep-disorder-management/
Rodriguez, P. J., Cartwright, B. M. G., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine, 184(9), 1056. https://doi.org/10.1001/jamainternmed.2024.2525
Sato, G., Uchino, H., & Hirose, T. (2024). Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study. Diabetes Therapy, 15(9), 2119–2130. https://doi.org/10.1007/s13300-024-01631-5
Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B. (2023). Do GLP-1 analogs have a place in the treatment of PCOS? New insights and promising therapies. Journal of Clinical Medicine, 12(18), 5915. https://doi.org/10.3390/jcm12185915